Wessels AM, Tariot PN, Zimmer JA, et al. - Researchers investigated whether lanabecestat slows the progression of Alzheimer disease (AD) compared with placebo in patients with early AD (mild cognitive impairment) and mild AD dementia. They performed two multicenter, global, double-blind studies at 257 and 251 centers in 15 and 18 countries or territories, respectively. AMARANTH included 2,218 randomized participants, of whom 539 individuals completed the study. DAYBREAK-ALZ included 1,722 (30.2%) randomized participants, of whom 76 individuals completed the study. In all, the researchers found that although lanabecestat was generally well tolerated, it did not slow cognitive or functional decline in individuals with early or mild AD dementia.